PDF(Pubmed)
Abstract：
UNASSIGNED: Olanzapine has already been used to treat schizophrenia patients; however, the initial dosage recommendation when multiple drugs are used in combination, remains unclear. The purpose of this study was to explore the drug-drug interaction (DDI) of multiple drugs combined with olanzapine and to recommend the optimal administration of olanzapine in schizophrenia patients.
UNASSIGNED: In this study, we obtained olanzapine concentrations from therapeutic drug monitoring (TDM) database. In addition, related medical information, such as physiological, biochemical indexes, and concomitant drugs was acquired using medical log. Sixty-five schizophrenia patients were enrollmented for analysis using population pharmacokinetic model by means of nonlinear mixed effect (NONMEM).
UNASSIGNED: Weight and combined use of aripiprazole significantly affected olanzapine clearance. Without aripiprazole, for once-daily olanzapine administration dosages, 0.6, 0.5 mg/kg/day were recommended for 40-70, and 70-100 kg schizophrenia patients, respectively; for twice-daily olanzapine administration dosages, 0.6, 0.5 mg/kg/day were recommended for 40-60, and 60-100 kg schizophrenia patients, respectively. With aripiprazole, for once-daily olanzapine administration dosages, 0.4, 0.3 mg/kg/day were recommended for 40-53, and 53-100 kg schizophrenia patients, respectively; for twice-daily olanzapine administration dosages, 0.4 mg/kg/day was recommended for 40-100 kg schizophrenia patients, respectively.
UNASSIGNED: Aripiprazole significantly affected olanzapine clearance, and when schizophrenia patients use aripiprazole, the olanzapine dosages need adjust. Meanwhile, we firstly recommended the optimal initial dosages of olanzapine in schizophrenia patients.
UNASSIGNED: In this study, we obtained olanzapine concentrations from therapeutic drug monitoring (TDM) database. In addition, related medical information, such as physiological, biochemical indexes, and concomitant drugs was acquired using medical log. Sixty-five schizophrenia patients were enrollmented for analysis using population pharmacokinetic model by means of nonlinear mixed effect (NONMEM).
UNASSIGNED: Weight and combined use of aripiprazole significantly affected olanzapine clearance. Without aripiprazole, for once-daily olanzapine administration dosages, 0.6, 0.5 mg/kg/day were recommended for 40-70, and 70-100 kg schizophrenia patients, respectively; for twice-daily olanzapine administration dosages, 0.6, 0.5 mg/kg/day were recommended for 40-60, and 60-100 kg schizophrenia patients, respectively. With aripiprazole, for once-daily olanzapine administration dosages, 0.4, 0.3 mg/kg/day were recommended for 40-53, and 53-100 kg schizophrenia patients, respectively; for twice-daily olanzapine administration dosages, 0.4 mg/kg/day was recommended for 40-100 kg schizophrenia patients, respectively.
UNASSIGNED: Aripiprazole significantly affected olanzapine clearance, and when schizophrenia patients use aripiprazole, the olanzapine dosages need adjust. Meanwhile, we firstly recommended the optimal initial dosages of olanzapine in schizophrenia patients.
摘要：
■奥氮平已经被用于治疗精神分裂症患者；然而，多种药物联合使用时的初始剂量建议，尚不清楚。目的探讨多药联合奥氮平的药物相互作用(DDI),推荐精神分裂症患者奥氮平的最佳给药方案。
■在这项研究中，我们从治疗药物监测(TDM)数据库获得奥氮平浓度.此外,相关医疗信息,比如生理，生化指标,并使用医疗日志获得伴随药物。65例精神分裂症患者通过非线性混合效应（NONMEM）使用群体药代动力学模型进行分析。
■体重和联合使用阿立哌唑显著影响奥氮平清除率。没有阿立哌唑,每天一次的奥氮平给药剂量，建议40-70和70-100kg精神分裂症患者为0.6，0.5mg/kg/天，分别为每日两次奥氮平给药剂量，建议40-60和60-100kg精神分裂症患者为0.6，0.5mg/kg/天，分别。阿立哌唑,每天一次的奥氮平给药剂量，建议40-53和53-100kg精神分裂症患者服用0.4、0.3mg/kg/天，分别为每日两次奥氮平给药剂量，40-100公斤精神分裂症患者推荐0.4毫克/公斤/天，分别。
■阿立哌唑显著影响奥氮平清除率，当精神分裂症患者使用阿立哌唑时，奥氮平的剂量需要调整。同时,我们首先推荐精神分裂症患者奥氮平的最佳初始剂量。
■在这项研究中，我们从治疗药物监测(TDM)数据库获得奥氮平浓度.此外,相关医疗信息,比如生理，生化指标,并使用医疗日志获得伴随药物。65例精神分裂症患者通过非线性混合效应（NONMEM）使用群体药代动力学模型进行分析。
■体重和联合使用阿立哌唑显著影响奥氮平清除率。没有阿立哌唑,每天一次的奥氮平给药剂量，建议40-70和70-100kg精神分裂症患者为0.6，0.5mg/kg/天，分别为每日两次奥氮平给药剂量，建议40-60和60-100kg精神分裂症患者为0.6，0.5mg/kg/天，分别。阿立哌唑,每天一次的奥氮平给药剂量，建议40-53和53-100kg精神分裂症患者服用0.4、0.3mg/kg/天，分别为每日两次奥氮平给药剂量，40-100公斤精神分裂症患者推荐0.4毫克/公斤/天，分别。
■阿立哌唑显著影响奥氮平清除率，当精神分裂症患者使用阿立哌唑时，奥氮平的剂量需要调整。同时,我们首先推荐精神分裂症患者奥氮平的最佳初始剂量。
